| Name | Title | Contact Details |
|---|
CRS Medical Technologies is a New Berlin, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
EmCare Holdings Inc. is one of the leading companies in Healthcare, Pharmaceuticals, & Biotech industry. EmCare Holdings Inc. is based in Dallas, TX. You can find more information on EmCare Holdings Inc. at www.emcare.com
John J. Morgan and David R. White founded MorganWhiteGroup, Inc. in 1987. The business started out primarily focusing on payroll deduction of supplemental insurance products, and has grown into what is today, a holding company made up of 6 wholly owned subsidiaries. The MorganWhiteGroup of companies now includes: Two sales agencies, MWG Employer Services and MWG Senior Healthcare, two third-party administrators (TPAs), MorganWhite Administrators, Inc. and MorganWhite Administrators International, a marketing agency, MWG Marketing, and a Reinsurance Intermediary, MWG Reinsurance, Inc. Our success since 1987 has been achieved by delivering insurance products to the marketplace that cannot be found anywhere else. Our company's guiding principal has been to find a market that is either under-served or not served at all and design a product to fit that market. At MorganWhiteGroup, we look forward to the challenge of solving customers’ medical, dental and vision insurance needs today, and in the future. We are committed to making the investment in technology, equipment, and personnel to provide our customers with the latest, most up to date tools available, to solve their insurance needs.
Cape Professional Billing, Inc. is a Cape May Court House, NJ-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.